AR068065A1 - Derivados de tetrahidroquinolinas, antagonistas de receptores de tsh, composiciones farmaceuticas que los contienen y usos de los mismos en enfermedades asociadas a desordenes tiroideos. - Google Patents

Derivados de tetrahidroquinolinas, antagonistas de receptores de tsh, composiciones farmaceuticas que los contienen y usos de los mismos en enfermedades asociadas a desordenes tiroideos.

Info

Publication number
AR068065A1
AR068065A1 ARP080103761A ARP080103761A AR068065A1 AR 068065 A1 AR068065 A1 AR 068065A1 AR P080103761 A ARP080103761 A AR P080103761A AR P080103761 A ARP080103761 A AR P080103761A AR 068065 A1 AR068065 A1 AR 068065A1
Authority
AR
Argentina
Prior art keywords
phenyl
quinolin
acetyl
tetrahydro
methyl
Prior art date
Application number
ARP080103761A
Other languages
English (en)
Inventor
W F J Karstens
P G M Conti
R Plate
C M Timmers
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of AR068065A1 publication Critical patent/AR068065A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicacion 1: Uso de los compuestos de acuerdo a la formula general (1) o una sal farmacéuticamente aceptable de la misma, donde R1es H o metilo; X es un enlace, O. NH o N(alquilo C1-4), R2 es C1-4alquilo, R5-alquilo C1-4 o R9-alquilo C2-4, si X es NH, R2 en adicion es R8-alcoxicarbonioI C1-2; o si X es un enlace, R2 en adicion es H, halogeno o heteroarilo C2-5 o fenilo, ambos sustituidos opcionalmente con uno o más sustituyentes seleccionados de alquilo C1-3, alcoxi C1-3 o halogeno; Y es un enlace, O o NH, mientras que si Y es un enlace, R3 es fenilo, opcionalmente sustituido con uno o más sustituyentes seleccionados de halogeno, hidroxi, metoxi, fenoxi, fenilo, C1-4alquilo, nitro, amino o (di)[alquilo C1-4]amino o R3 es R6-alquilo C1-6, R6-cicloalquilo C3-6, R7-oxialquilo C1-6, o 2-piridil o es un heteroarilo de 5 miembros, opcionalmente substituido con uno o más sustituyentes seleccionados de alcoxi C1-3, alquilo C1-3 o halogeno; si Y es O, R3, es R6-alquilo C1-6, R7-oxialquilo C2-6 o cicloalquilo C3-7; y si Y es NH, R3 es R6-alquilo C1-6, R7-oxialquilo C2-6; R4 es H, (di)[alquil C1-3]amino o alcoxi C1-3; R5 es CN o piridilo; R6 es H, o cicloalquilo C3-5, heteroarilo C2-5 o fenilo, los ultimos tres grupos opcionalmente substituido con uno o más sustituyentes seleccionados de halogeno, alcoxi C1-4, o alquilo C1-4, los ultimos grupos ambos opcionalmente sustituidos con uno o más halogenos; R7 es heteroarilo C2-5 o fenilo, ambos opcionalmente substituido con uno o más sustituyentes seleccionados de halogeno, alcoxi C1-4 o alquilo C1-4; R8 es H o heteroarilo C2-5 o fenilo. ambos sustituidos opcionalmente con uno o más sustituyentes seleccionados de alquilo C1-3, alcoxi C1-3, o halogeno; y R9 es (di)[alquil C1-4]amino o heterocicloalquilo C2-6 caracterizado porque sirve para preparar un medicamento para el tratamiento o prevencion de desordenes sensibles a las rutas mediadas por el receptor de TSH. Reivindicacion 8: Un compuesto caracterizado porque es seleccionado del grupo de: ácido hexanoico (1-acetil-2,2,4-dimetil-4-fenil-1,2,3,4-tetrahidro-quinolin-6-il)-amida, ácido 1-metil-1H-pirrol-2-carboxílico (1-acetil-2,2,4-dimetil-4-fenil-1,2,3,4-tetrahidro-quinolin-6-il)-amida, N-(1-acetil-2,2,4-trimetil-4-fenil-1,2,3,4-tetrahidro-quinolin-6-il)-5-bromo-2-metilamino-benzamida, ácido piridino-2-carboxílico (1-acetil-2,2,4-dimetil-4-fenil-1,2,3,4-tetrahidro-quinolin-6-il)-amida, N-(1-acetil-2,2,4-trimetil-4-fenil-1,2,3,4-tetrahidro-quinolin-6-il)-3,4-dimetil-benzamida, 2-fenoxi-etil éster del ácido (1-acetil-2,2,4-trimetil-4-fenil-1,2,3,4-tetrahidro-quinolin-6-il)-carbámico, butil éster del ácido (1-acetil-2,2,4-trimetil-4-fenil-1,2,3,4-tetrahidro-quinolin-6-il)-carbámico, 1-(1-acetil-2,2,4-trimetil-4-fenil-1,2,3,4-tetrahidro-quinolin-6-il)-3-ciclopentil-urea, ácido hexanoico [1-acetil-4-(4-bromo-fenil)-4-metil-1,2,3,4-tetrahidro-quinolin-6-il]-amida, N-(1-acetil-4-metil-4-fenil-1,2,3,4-tetrahidro-quinolin-6-il)-2-fenoxi-acetamida, N-(1-acetil-4-metil-4-fenil-1,2,3,4-tetrahidro-quinolin-6-il)-3-(3-cloro-fenil)-propionamida, N-(1-acetil-4-metil-4-fenil-1,2,3,4-tetrahidro-quinolin-6-il)-3-tiofen-2-il-propionamida, 1-(1-acetil-4-metil-4-fenil-1,2,3,4-tetrahidro-quinolin-6-il)-3-(4-clorobencil)-urea, ácido hexanoico {1-acetil-4-[4-(3-fluoro-piridin-4-il)-fenil]-4-metil-1,2,3,4-tetrahidro-quinolin-6-il}-amida, 3-cloro-bencil éster del ácido [4-(1-acetil-6-hexanoilamino-4-metil-1,2,3,4-tetrahidro-quinolin-4-iI)-fenil]-carbámico, metil éster del ácido [4-(1-acetil-6-hexanoilamino-4-metil-1,2,3,4-tetrahidro-quinolin-4-iI)-fenil]-carbámico, ácido ciclopentanocarboxilico (1-acetil-7-dimetilamino-2,2,4-trimetil-4-fenil-1,2,3,4-tetrahidro-quinolin-6-il)-amida, N-(1-acetil-7-dimetilamino-2,2,4-trimetil-4-fenil-1,2,3,4-tetrahidro-quinolin-6-il)-3-(4-clorofenil)-propionamida, 1-(1-acetil-7-dimetilamino-4-metil-4-fenil-1,2,3,4-tetrahidro-quinolin-6-il)-3-(2-metoxi-bencil)-urea, tiofen-2-ilmetil éster del ácido (1-acetil-7-dimetilamino-4-metil-4-fenil-1,2,3,4-tetrahidro-quinolin-6-il)-carbámico, ácido bifenil-4-carboxílico (1-acetil-7-metoxi-2,2,4-trimetil-4-fenil-1,2,3,4-tetrahidro-quinolin-6-il)-amida, ácido furan-2-carboxílico (1-acetil-7-metoxi-4-(4-metoxi-fenil)-1,2,3,4-tetrahidro-quinolin-6-il)-amida, ácido bifenil-4-carboxílico (1-acetil-4-(4-cianometoxi-fenil)-2,2,4-trimetil-4-fenil-1,2,3,4-tetrahidro-quinolin-6-il)-amida, ácido bifenil-4-carboxílico {1-acetil-2,2,4-trimetil-4[4-(piridin-4-metoxi)-fenil]-1,2,3,4-tetrahidro-quinolin-6-il}-amida, furan-2-ilmetiI éster del ácido [4-(1-acetil-6-hexanoilamino-4-metil-1,2,3,4-tetrahidro-quinolin-4-il)-fenil]-carbámico, N-(1-acetil-2,2,4-trimetil-4-fenil-1,2,3,4-tetrahidro-quinolin-6-il)-3-(3-clorofenil)-propionamida, 3-metil-butil éster del ácido (1-acetil-4-metil-4-fenil-1,2,3,4-tetrahidro-quinolin-6-il)-carbámico, 1-metil-ciclopropilmetil éster del ácido (1-acetil-4-metil-4-fenil-1,2,3,4-tetrahidro-quinolin-6-il)-carbámico, ciclobutiImetil éster del ácido (1-acetil-4-metil-4-fenil-1,2,3,4-tetrahidro-quinolin-6-il)-carbámico, (R)-1,2-dimetil-propil éster del ácido (1-acetil-4-metil-4-fenil-1,2,3,4-tetrahidro-quinolin-6-il)-carbámico, (1R,2S,4S)-biciclo[2.2.1]hept-2-il éster del ácido (1-acetil-4-metil-4-fenil-1,2,3,4-tetrahidro-quinolin-6-il)-carbámico, ciclopentil éster del ácido (1-acetil-4-metil-4-fenil-1,2,3,4-tetrahidro-quinolin-6-il)-carbámico, N-(1-acetil-4-metil-4-fenil-1,2,3,4-tetrahidro-quinolin-6-il)-3-(3-trifluorometil-fenil)-propionamida, 3-cloro-4-fluoro-bencil éster del ácido (1-acetil-4-metil-4-fenil-1,2,3,4-tetrahidro-quinolin-6-il)-carbámico, ácido 5-bromo-tiofeno-2-carboxílico (1-acetil-4-metil-4-fenil-1,2,3,4-tetrahidro-quinolin-6-il)-amida, (+)-1-(1-acetil-4-metil-4-fenil-1,2,3,4-tetrahidro-quinolin-6-il)-3-(4-cloro-bencil)-urea, (+)-N-(1-acetil-2,2,4-trimetil-4-fenil-1,2,3,4-tetrahidro-quinolin-6-il)-3-(3-cloro-fenil)-propionamida, (+)-N-(1-acetil-4-metil-4-fenil-1,2,3,4-tetrahidro-quinolin-6-il)-3-(3-trifluorometil-fenil)-propionamida, ciclopentil éster del ácido (+)-(1-acetil-4-metil-4-fenil-1,2,3,4,4a,8a-hexahidro-quinolin-6-il)-carbámico, o 3-cloro-4-fluoro-bencil éster del ácido (+)-(1-acetil-4-metil-4-fenil-1,2,3,4-tetrahidro-quinolin-6-iI)-carbámico.
ARP080103761A 2007-08-31 2008-08-29 Derivados de tetrahidroquinolinas, antagonistas de receptores de tsh, composiciones farmaceuticas que los contienen y usos de los mismos en enfermedades asociadas a desordenes tiroideos. AR068065A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07115368 2007-08-31
EP08150398 2008-01-18

Publications (1)

Publication Number Publication Date
AR068065A1 true AR068065A1 (es) 2009-11-04

Family

ID=40387927

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103761A AR068065A1 (es) 2007-08-31 2008-08-29 Derivados de tetrahidroquinolinas, antagonistas de receptores de tsh, composiciones farmaceuticas que los contienen y usos de los mismos en enfermedades asociadas a desordenes tiroideos.

Country Status (13)

Country Link
US (1) US9174940B2 (es)
EP (1) EP2197445B1 (es)
JP (1) JP5467044B2 (es)
KR (1) KR20100063105A (es)
CN (1) CN101790376B (es)
AR (1) AR068065A1 (es)
AU (1) AU2008292134B2 (es)
CA (1) CA2695503A1 (es)
CL (1) CL2008002566A1 (es)
MX (1) MX2010002192A (es)
PE (1) PE20090955A1 (es)
TW (1) TW200918058A (es)
WO (1) WO2009027482A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090124651A1 (en) 2007-08-31 2009-05-14 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
EP2753928B1 (en) * 2011-09-09 2018-02-07 Quidel Corporation Compositions and methods for detecting autoantibodies
UA117165C2 (uk) * 2014-01-09 2018-06-25 Оріон Корпорейшн Біциклічні гетероциклічні похідні як інгібітори бромодомену
KR101686881B1 (ko) * 2014-07-25 2016-12-20 연세대학교 산학협력단 스타틴을 포함하는 갑상선 안병증의 예방 또는 치료용 약제학적 조성물
TW202408996A (zh) * 2022-06-30 2024-03-01 日商橘生藥品工業股份有限公司 3,4-二氫喹啉-2(1h)-酮化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4237430C1 (de) * 1992-11-05 1994-03-17 Henning Berlin Gmbh Aufgereinigtes TSH-Präparat, Verfahren zu seiner Herstellung und seine Verwendung zur Herstellung von TSH-Tracern für TSH-Rezeptorassays und in TSH-Rezeptorassays
JPH0789991A (ja) * 1993-09-28 1995-04-04 Mitsubishi Chem Corp 新規なポリペプチドおよびそれを用いるｔｓｈ受容体抗体の測定法
JPH09140386A (ja) * 1995-11-22 1997-06-03 Eiken Chem Co Ltd 甲状腺機能を刺激する活性を持つ抗体
EP1406628B1 (en) * 2001-07-02 2006-03-08 Akzo Nobel N.V. Tetrahydroquinoline derivatives
TWI322012B (en) * 2002-12-20 2010-03-21 Organon Nv Tetrahydroquinoline derivatives
TWI306855B (en) * 2002-12-20 2009-03-01 Organon Nv Tetrahydroquinoline derivatives
ATE339523T1 (de) * 2003-06-20 2006-10-15 Serum Biomedical Inst Verfahren zur herstellung von rekombinanten nukleinsäuremolekülen

Also Published As

Publication number Publication date
PE20090955A1 (es) 2009-07-23
EP2197445A2 (en) 2010-06-23
KR20100063105A (ko) 2010-06-10
CN101790376A (zh) 2010-07-28
CL2008002566A1 (es) 2009-01-02
CA2695503A1 (en) 2009-03-05
TW200918058A (en) 2009-05-01
WO2009027482A2 (en) 2009-03-05
US20110172267A1 (en) 2011-07-14
JP5467044B2 (ja) 2014-04-09
JP2010536934A (ja) 2010-12-02
EP2197445B1 (en) 2017-04-19
MX2010002192A (es) 2010-03-17
US9174940B2 (en) 2015-11-03
AU2008292134A1 (en) 2009-03-05
CN101790376B (zh) 2013-06-12
AU2008292134B2 (en) 2013-06-13
WO2009027482A3 (en) 2009-05-28

Similar Documents

Publication Publication Date Title
RU2403247C2 (ru) Модуляторы никотиновых ацетилхолиновых рецепторов альфа 7 и их терапевтические применения
RU2388750C2 (ru) Ингибиторы фосфодиэстеразы 4, включая аналоги n-замещенного диариламина
RU2424240C2 (ru) Антибактериальные производные пиперидина
RU2458920C2 (ru) Новые соединения
RU2395506C2 (ru) Антагонисты рецептора хемокина
RU2404982C2 (ru) Применение соединений пирролохинолина для уничтожения клинически латентных микроорганизмов
AR048691A1 (es) Compuestos con estructura de alquino con accion antagonista de mch y medicamentos que contienen estos compuestos
HRP20191821T1 (hr) Antiproliferativni spojevi i načini njihove uporabe
RU2394031C2 (ru) Соли четвертичного аммония в качестве антагонистов м3
PE20090123A1 (es) Un derivado heterociclico conteniendo nitrogeno y un farmaco conteniendo el mismo como el ingrediente activo
PE20090218A1 (es) Compuestos mimeticos de glucocorticoides, metodos de preparacion y composiciones farmaceuticas
RU2221796C2 (ru) Производные аминов
AR068065A1 (es) Derivados de tetrahidroquinolinas, antagonistas de receptores de tsh, composiciones farmaceuticas que los contienen y usos de los mismos en enfermedades asociadas a desordenes tiroideos.
PE20121509A1 (es) Compuestos de triazolopiridinas como inhibidores de quinasa mps-1
AR055015A1 (es) Derivados fusionados de pirazol composicion farmaceutica y uso del compuesto para fabricar medicamentos.
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
AR036115A1 (es) Compuesto de n-aroilaminas, composiciones farmaceuticas formuladas con dichos compuestos; uso de los compuestos mencionados en la preparacion de composiciones farmaceuticas para tratar,prevenir enfermedades o trastornos donde se requiere la aplicacion de antagonistas de receptores de la orexina huma
EA200700027A1 (ru) Антагонисты рецептора глюкагона, их получение и терапевтическое применение
AR049276A1 (es) Compuestos carboxamidos opiodes y composiciones farmaceuticas que los contienen
PE20050874A1 (es) Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4
AR058587A1 (es) Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos
AR031556A1 (es) Derivados de 3-(diarilmetilen)-8-azabiciclo[3.2.1] octano y composiciones farmaceuticas que los comprenden
AR056883A1 (es) Derivados de 7-azaindol-2 carboxamida, un proceso para la preparacion de los mismos, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades asociadas con la modulacion de receptores de h3
RU2006139946A (ru) Производные пиперазинилпиперидина в качестве антагонистов хемокинового рецептора
RU2017145930A (ru) МОДУЛЯТОРЫ ROR ГАММА (RORγ)

Legal Events

Date Code Title Description
FB Suspension of granting procedure